{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:57:43Z","timestamp":1792162663587,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.biopsych.2016.11.014","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T13:21:41Z","timestamp":1481808101000},"page":"8-16","source":"Crossref","is-referenced-by-count":141,"title":["Bitopertin in Negative Symptoms of Schizophrenia\u2014Results From the Phase III FlashLyte and DayLyte Studies"],"prefix":"10.1016","volume":"82","author":[{"given":"Dragana","family":"Bugarski-Kirola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3270-0293","authenticated-orcid":false,"given":"Thomas","family":"Blaettler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang W.","family":"Fleischhacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo A.","family":"Bressan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Napieralski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Ochi-Lohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0288-309X","authenticated-orcid":false,"given":"Stephen R.","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2016.11.014_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archpsyc.58.2.165","article-title":"A separate disease within the syndrome of schizophrenia","volume":"58","author":"Kirkpatrick","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/appi.ajp.162.3.495","article-title":"Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up","volume":"162","author":"Milev","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.schres.2013.07.026","article-title":"Pharmacological approaches to treating negative symptoms: A review of clinical trials","volume":"150","author":"Arango","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2016.11.014_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40501-016-0075-8","article-title":"Treating negative symptoms in schizophrenia: An update","volume":"3","author":"Remington","year":"2016","journal-title":"Curr Treat Options Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib5","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jpsychires.2013.01.024","article-title":"Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts","volume":"47","author":"Liemburg","year":"2013","journal-title":"J Psychiatr Res"},{"issue":"suppl 3","key":"10.1016\/j.biopsych.2016.11.014_bib6","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1093\/schbul\/sbu006","article-title":"Schizophrenia\u2014time to commit to policy change","volume":"40","author":"Fleischhacker","year":"2014","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2016.11.014_bib7","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2003.09.012","article-title":"Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia","volume":"55","author":"Tsai","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0006-3223(98)00279-0","article-title":"D-serine added to antipsychotics for the treatment of schizophrenia","volume":"44","author":"Tsai","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib10","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/archpsyc.62.11.1196","article-title":"Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study","volume":"62","author":"Lane","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1192\/bjp.169.5.610","article-title":"Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia","volume":"169","author":"Heresco-Levy","year":"1996","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib12","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","article-title":"The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments","volume":"164","author":"Buchanan","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib13","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.4088\/JCP.11m07031","article-title":"A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia","volume":"73","author":"Weiser","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib14","first-page":"468","article-title":"Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification","volume":"12","author":"Javitt","year":"2009","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.biopsych.2016.11.014_bib15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2016.11.014_bib17","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"10.1016\/j.biopsych.2016.11.014_bib18","series-title":"Diagnostics and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR)","year":"2000"},{"key":"10.1016\/j.biopsych.2016.11.014_bib19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2016.11.014_bib20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0920-9964(92)90003-N","article-title":"Reliability and validity of a depression rating scale for schizophrenics","volume":"6","author":"Addington","year":"1992","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2016.11.014_bib21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the extrapyramidal symptom rating scale (ESRS)","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2016.11.014_bib22","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2016.11.014_bib23","series-title":"Good Clinical Practice Guide","year":"2014"},{"key":"10.1016\/j.biopsych.2016.11.014_bib24","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1600-0447.2000.101004323.x","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.biopsych.2016.11.014_bib26","series-title":"ECDEU Assessment Manual for Psychopharmacology\u2014Revised (DHEW Publication No. ADM 76-338)","first-page":"218","author":"Guy","year":"1976"},{"issue":"s416","key":"10.1016\/j.biopsych.2016.11.014_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1034\/j.1600-0447.107.s416.5.x","article-title":"The Clinical Global Impression-Schizophrenia scale: A simple instrument to measure the diversity of symptoms present in schizophrenia","volume":"107","author":"Haro","year":"2003","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"s438","key":"10.1016\/j.biopsych.2016.11.014_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.2008.01308.x","article-title":"Definitions of response and remission in schizophrenia: Recommendations for their use and their presentation","volume":"119","author":"Leucht","year":"2009","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.biopsych.2016.11.014_bib29","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/sj.npp.1301325","article-title":"Defining \u201cresponse\u201d in antipsychotic drug trials: Recommendations for the use of scale-derived cutoffs","volume":"32","author":"Leucht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2016.11.014_bib30","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.schres.2013.07.058","article-title":"Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia","volume":"150","author":"Marder","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2016.11.014_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fpsyt.2013.00151","article-title":"Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis","volume":"4","author":"Merritt","year":"2013","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neulet.2015.08.039","article-title":"Supplementation of antipsychotic treatment with sarcosine\u2014GlyT1 inhibitor\u2014causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia","volume":"606","author":"Strzelecki","year":"2015","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.biopsych.2016.11.014_bib34","unstructured":"Dunayevich E, Buchanan R, Chen C-Y, Dietrich J, Sun H, Marder S (2015): Efficacy and safety of the glycine transporter type-1 inhibitor Amg 747 for the treatment of negative symptoms associated with schizophrenia. Poster presented at the 54th Annual Meeting of the American College of Neuropsychopharmacology, December 6\u201310, 2015, Hollywood, Florida."},{"key":"10.1016\/j.biopsych.2016.11.014_bib35","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.neuropharm.2011.11.008","article-title":"Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia","volume":"62","author":"Alberati","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2016.11.014_bib36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/JCP.0000000000000073","article-title":"The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial","volume":"34","author":"Schoemaker","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2016.11.014_bib37","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/npp.2011.306","article-title":"Randomized, placebo-controlled trials of antidepressants for acute major depression: Thirty-year meta-analytic review","volume":"37","author":"Undurraga","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2016.11.014_bib38","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1176\/appi.ajp.2013.12030315","article-title":"Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010","volume":"170","author":"Agid","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3371\/CSRP.5.2.5","article-title":"Training for assessment of negative symptoms of schizophrenia across languages and cultures: Comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factor","volume":"5","author":"Daniel","year":"2011","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"Suppl 2","key":"10.1016\/j.biopsych.2016.11.014_bib40","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1093\/schbul\/sbt197","article-title":"A review of reward processing and motivational impairment in schizophrenia","volume":"40","author":"Strauss","year":"2014","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2016.11.014_bib41","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/schbul\/sbn094","article-title":"Negative symptoms in schizophrenia: Avolition and Occam\u2019s razor","volume":"36","author":"Foussias","year":"2010","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2016.11.014_bib42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/archgenpsychiatry.2011.129","article-title":"Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia","volume":"69","author":"Grant","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib43","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2012.06.029","article-title":"Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists","volume":"150","author":"Papouin","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.biopsych.2016.11.014_bib44","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/cercor\/bhr130","article-title":"Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex","volume":"22","author":"Fossat","year":"2012","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.biopsych.2016.11.014_bib45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.biopsych.2009.08.026","article-title":"Functional and dysfunctional synaptic plasticity in prefrontal cortex: Roles in psychiatric disorders","volume":"67","author":"Goto","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.11.014_bib46","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/14728222.2014.934225","article-title":"Targeting of NMDA receptors in new treatments for schizophrenia","volume":"18","author":"Hashimoto","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.biopsych.2016.11.014_bib47","doi-asserted-by":"crossref","first-page":"141","DOI":"10.31887\/DCNS.2007.9.2\/rbonelli","article-title":"Frontal-subcortical circuitry and behavior","volume":"9","author":"Bonelli","year":"2007","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.biopsych.2016.11.014_bib48","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-neuro-061010-113641","article-title":"Modulation of striatal projection systems by dopamine","volume":"34","author":"Gerfen","year":"2011","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.biopsych.2016.11.014_bib49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/acps.12231","article-title":"Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?","volume":"130","author":"Corves","year":"2014","journal-title":"Acta Psychiatr Scand"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322316331092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322316331092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T07:28:24Z","timestamp":1658042904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322316331092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0006322316331092"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2016.11.014","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}